A simple, cost-effective microfluidic device using a 3D cross-flow T-junction for producing decellularized extracellular matrix-derived microcarriers

Farah Kamar,Connor J Gillis,Grace Bischoff,Anorin Ali,John R de Bruyn,Lauren Elizabeth Flynn,Tamie Lynn Poepping

DOI: https://doi.org/10.1101/2024.10.30.621138

2024-11-03

Abstract:Cell therapies using human mesenchymal stromal cells (MSCs) are promising for a wide variety of clinical applications. However, broad-scale clinical translation is limited by conventional culture methods for MSC expansion within 2D tissue-culture flasks. MSC expansion on ECM-derived microcarriers within stirred bioreactor systems offers a promising approach to support MSC growth. Previously, our team established methods for fabricating ECM-derived microcarriers from a variety of decellularized tissue sources using electrospraying techniques. However, these microcarriers are relatively large and have a broad size distribution, which may limit their utility. Smaller and more uniform microcarriers may be favorable for MSC growth within bioreactors and have greater potential to serve as a minimally invasive injectable cell delivery platform. To address these limitations, the current project focused on the development of a new microfluidic-based approach enabling both uniform and small microcarrier production. Using a novel, modified 3D T-junction design, we successfully generated microcarriers using human decellularized adipose tissue (DAT) as the ECM source. Our new cost-effective device produced microbeads that were small and monodisperse, at a range of flow rate combinations and with high production rates. Photo-crosslinking using rose bengal allowed for the generation of microcarriers that were stable following rehydration, with a mean diameter of 196 +/- 47 micrometers. Following methods optimization and microcarrier characterization, in vitro studies confirmed that the new microcarriers supported human adipose-derived stromal cell (hASC) attachment and growth, as well as ECM production, across 14 days within spinner flask bioreactors. Overall, this study demonstrates the feasibility of using our novel, cost-effective, and reusable microfluidics device to generate cell-supportive microcarriers comprised exclusively of ECM in a size range that could be injected via a small gauge needle and were stable in long-term culture.

Bioengineering

What problem does this paper attempt to address?

The problem that this paper attempts to solve is that when using human mesenchymal stromal cells (MSCs) in cell therapy, the cell expansion methods in traditional two - dimensional tissue culture flasks have limitations, which restrict their large - scale clinical applications. Specifically, these limitations include cell senescence phenomena, such as changes in cell morphology, weakened proliferation and differentiation abilities, and altered secretomes. In addition, traditional microcarriers are relatively large in size and unevenly distributed, which may affect the attachment and growth of MSCs and limit their potential application as minimally invasive injection cell - delivery platforms.

To overcome these limitations, this article proposes a new microfluidic technology that utilizes an improved 3D cross - flow T - junction design to achieve the production of uniform and small extracellular matrix (ECM) - derived microcarriers. This new - type device can efficiently generate small and monodisperse microbeads at a relatively low cost, is suitable for long - term cell culture, and has the possibility of injection through fine needles. Through optimization methods and microcarrier characterization, in - vitro studies have shown that the newly generated microcarriers support the attachment and growth of human adipose - derived mesenchymal stem cells (hASCs) and the production of extracellular matrix within a stirred bioreactor for 14 days. This indicates that by using this new, cost - effective, and reusable microfluidic device, cell - supportive microcarriers composed entirely of ECM can be generated, and the size range of these microcarriers is suitable for minimally invasive injection and remains stable during long - term culture.